Analyst Price Target is $29.17
▲ +92.39% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Celcuity in the last 3 months. The average price target is $29.17, with a high forecast of $42.00 and a low forecast of $23.00. The average price target represents a 92.39% upside from the last price of $15.16.
Current Consensus is
Buy
The current consensus among 7 investment analysts is to buy stock in Celcuity.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Read More